STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironment.

Autor: Benoit A; Lady Davis Institute, Jewish General Hospital, 3755 Côte Sainte-Catherine Road, Montreal, QC, H3T 1E2, Canada.; Division of Experimental Medicine, McGill University, Montreal, QC, Canada., Abraham MJ; Lady Davis Institute, Jewish General Hospital, 3755 Côte Sainte-Catherine Road, Montreal, QC, H3T 1E2, Canada.; Division of Experimental Medicine, McGill University, Montreal, QC, Canada., Li S; Lady Davis Institute, Jewish General Hospital, 3755 Côte Sainte-Catherine Road, Montreal, QC, H3T 1E2, Canada., Kim J; Lady Davis Institute, Jewish General Hospital, 3755 Côte Sainte-Catherine Road, Montreal, QC, H3T 1E2, Canada.; University of British Columbia, Vancouver, BC, Canada., Estrada-Tejedor R; Organic and Pharmaceutical Chemistry Department, IQS School of Engineering, Universitat Ramon Llull, Barcelona, Spain., Bakadlag R; Lady Davis Institute, Jewish General Hospital, 3755 Côte Sainte-Catherine Road, Montreal, QC, H3T 1E2, Canada.; Division of Experimental Medicine, McGill University, Montreal, QC, Canada., Subramaniam N; Lady Davis Institute, Jewish General Hospital, 3755 Côte Sainte-Catherine Road, Montreal, QC, H3T 1E2, Canada.; Division of Experimental Medicine, McGill University, Montreal, QC, Canada., Makhani K; Lady Davis Institute, Jewish General Hospital, 3755 Côte Sainte-Catherine Road, Montreal, QC, H3T 1E2, Canada.; Division of Experimental Medicine, McGill University, Montreal, QC, Canada., Guilbert C; Lady Davis Institute, Jewish General Hospital, 3755 Côte Sainte-Catherine Road, Montreal, QC, H3T 1E2, Canada., Tu R; Lady Davis Institute, Jewish General Hospital, 3755 Côte Sainte-Catherine Road, Montreal, QC, H3T 1E2, Canada.; Department of Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada., Salaciak M; Lady Davis Institute, Jewish General Hospital, 3755 Côte Sainte-Catherine Road, Montreal, QC, H3T 1E2, Canada.; Division of Experimental Medicine, McGill University, Montreal, QC, Canada., Klein KO; Lady Davis Institute, Jewish General Hospital, 3755 Côte Sainte-Catherine Road, Montreal, QC, H3T 1E2, Canada., Coyle KM; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada., Hilton LK; Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada., Santiago R; Department of Pediatrics, Faculty of Medicine, Universite Laval, Quebec City, QC, Canada., Dmitrienko S; Division of Pathology, McGill University Health Centre, Montreal, QC, Canada., Assouline S; Lady Davis Institute, Jewish General Hospital, 3755 Côte Sainte-Catherine Road, Montreal, QC, H3T 1E2, Canada.; Division of Experimental Medicine, McGill University, Montreal, QC, Canada.; Department of Oncology, McGill University, Montreal, QC, Canada., Morin RD; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada., Del Rincon SV; Lady Davis Institute, Jewish General Hospital, 3755 Côte Sainte-Catherine Road, Montreal, QC, H3T 1E2, Canada.; Division of Experimental Medicine, McGill University, Montreal, QC, Canada., Johnson NA; Lady Davis Institute, Jewish General Hospital, 3755 Côte Sainte-Catherine Road, Montreal, QC, H3T 1E2, Canada.; Division of Experimental Medicine, McGill University, Montreal, QC, Canada.; Department of Oncology, McGill University, Montreal, QC, Canada., Mann KK; Lady Davis Institute, Jewish General Hospital, 3755 Côte Sainte-Catherine Road, Montreal, QC, H3T 1E2, Canada. koren.mann@mcgill.ca.; Division of Experimental Medicine, McGill University, Montreal, QC, Canada. koren.mann@mcgill.ca.; Department of Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada. koren.mann@mcgill.ca.
Jazyk: angličtina
Zdroj: International journal of hematology [Int J Hematol] 2024 Mar; Vol. 119 (3), pp. 275-290. Date of Electronic Publication: 2024 Jan 29.
DOI: 10.1007/s12185-023-03692-x
Abstrakt: Diffuse large B-cell lymphoma (DLBCL) relapses in approximately 40% of patients following frontline therapy. We reported that STAT6 D419  mutations are enriched in relapsed/refractory DLBCL (rrDLBCL) samples, suggesting that JAK/STAT signaling plays a role in therapeutic resistance. We hypothesized that STAT6 D419 mutations can improve DLBCL cell survival by reprogramming the microenvironment to sustain STAT6 activation. Thus, we investigated the role of STAT6 D419 mutations on DLBCL cell growth and its microenvironment. We found that phospho-STAT6 D419N was retained in the nucleus longer than phospho-STAT6 WT following IL-4 stimulation, and STAT6 D419N recognized a more restricted DNA-consensus sequence than STAT6 WT. Upon IL-4 induction, STAT6 D419N expression led to a higher magnitude of gene expression changes, but in a more selective list of gene targets compared with STAT WT . The most significantly expressed genes induced by STAT6 D419N were those implicated in survival, proliferation, migration, and chemotaxis, in particular CCL17. This chemokine, also known as TARC, attracts helper T-cells to the tumor microenvironment, especially in Hodgkin's lymphoma. To this end, in DLBCL, phospho-STAT6 + rrDLBCL cells had a greater proportion of infiltrating CD4 + T-cells than phospho-STAT6 - tumors. Our findings suggest that STAT6 D419 mutations in DLBCL lead to cell autonomous changes, enhanced signaling, and altered composition of the tumor microenvironment.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: